WASHINGTON, D.C. (April 27, 2021) —
The Ensuring Access to Lower-Cost Medicines for Seniors Act (HR 2846) could save America’s seniors with Medicare Part D coverage more than $4 billion a year by lowering their out-of-pocket spending on prescription drugs and restoring the original intent of the Medicare Part D program. The Association for Accessible Medicines endorses The Ensuring Access to Lower-Cost Medicines for Seniors Act and thanks Reps. McKinley and Kuster for their leadership in introducing it.
ATTRIBUTE TO: AAM
AAM is driven by the belief that access to safe, quality, effective medicine has a tremendous impact on a person’s life and the world around them. Generic and biosimilar medicines improve people’s lives, improving society and the economy in turn. AAM represents the manufacturers and distributors of finished generic pharmaceuticals and biosimilars, manufacturers and distributors of bulk pharmaceutical chemicals, and suppliers of other goods and services to the generic industry. Generic pharmaceuticals are 90 percent of prescriptions dispensed in the U.S. but only 20 percent of total drug spending.
About the Biosimilars Council
The Biosimilars Council, a division of the Association for Accessible Medicines (AAM), works to ensure a positive environment for patient access to biosimilar medicines. The Biosimilars Council is a leading source for information about the safety and efficacy of more affordable alternatives to costly brand biologic medicines. Areas of focus include public and health expert education, strategic partnerships, government affairs, legal affairs and regulatory policy. More information is available at www.biosimilarscouncil.org.